Provided are 2&rsquo；,4&rsquo；-difluoro-2&rsquo；-methyl substituted nucleoside phosphoramidate derivative compounds of the general formula I, where the variables are as defined in the specification. Examples of the compounds include (S)-2-{ [(2S,3S,4R,SR)-S-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxyphosphorylamino} -propionic acid isopropyl ester and (S)-2-[[(2S,3S,4R,SR)-S-(S-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-2-yloxy)-phosphorylamino]-propionic acid isopropyl ester. The compounds are inhibitors of hepatitis C virus (HCV) RNA replication.
